• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Blue Foundry Bancorp Names Elizabeth Varki Jobes, Esq. to Board of Directors

    1/5/23 5:07:32 PM ET
    $BLFY
    Banks
    Finance
    Get the next $BLFY alert in real time by email

    RUTHERFORD, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Blue Foundry Bancorp (NASDAQ:BLFY) (the "Company"), announced today the appointment of Elizabeth Varki Jobes, Esq. as a Director, effective immediately.

    James D. Nesci, President and Chief Executive Officer stated, "We are excited to welcome Ms. Jobes to Blue Foundry's Board of Directors. Her years of combined legal and compliance experience leading large, global companies will bring additional perspective to our Board and will prove to be instrumental at Blue Foundry."

    Ms. Jobes serves as Senior Vice President and Global Chief Compliance Officer of Amryt Pharmaceuticals, a global commercial-stage pharmaceutical company, since 2020. Before joining Amryt, Jobes served as Senior Vice President and Chief Compliance Officer of North America at EMD Serono. Ms. Jobes also served in leadership roles at Spark Therapeutics, Auxilium Pharmaceutical, and Cephalon. Prior to her career in the pharmaceuticals industry, Jobes held various roles within Philadelphia's District Attorney's Office from 1991 to 2006.

    Ms. Jobes' service on several boards demonstrates her invaluable leadership skills. She currently serves on the board of Ampio Pharmaceuticals, a public company, as well as the board of a private biopharmaceutical company (Eyam Vaccines and Immunotherapeutics), and the board of a not-for-profit organization.

    Ms. Jobes is a member of the South Asian Bar Association and was a former board member of Women's Way. She received her law degree from Rutgers University School of Law and is licensed to practice in both New Jersey and Pennsylvania.

    Ms. Jobes commented, "I am eager to join Blue Foundry's innovative culture and dynamic leadership team. I look forward to leveraging my experience to build upon the Bank's exceptional reputation."

    About Blue Foundry Bancorp and Blue Foundry Bank

    Blue Foundry Bancorp is the holding company for Blue Foundry Bank, a place where things are made, purpose is formed, and ideas are crafted. Headquartered in Rutherford NJ, with presence in Bergen, Essex, Hudson, Morris, Passaic and Somerset counties, Blue Foundry Bank is a full-service, innovative bank serving the doers, movers, and shakers in our communities. We offer individuals and businesses alike the tailored products and services they need to build their futures. With a rich history dating back more than 145 years, Blue Foundry Bank has a longstanding commitment to its customers and communities. 

    Contacts:

    James D. Nesci 

    President and Chief Executive Officer

    bluefoundrybank.com

    [email protected] 

    201-972-8900



    Primary Logo

    Get the next $BLFY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLFY

    DatePrice TargetRatingAnalyst
    5/17/2023$9.50Neutral
    Piper Sandler
    1/25/2023Buy → Neutral
    Compass Point
    8/30/2022$13.25Mkt Perform
    Keefe Bruyette
    More analyst ratings

    $BLFY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP and Chief Tech Officer Malkiman Aleksandr bought $8,804 worth of shares (1,000 units at $8.80), increasing direct ownership by 6% to 18,100 units (SEC Form 4)

      4 - Blue Foundry Bancorp (0001846017) (Issuer)

      6/6/25 2:27:50 PM ET
      $BLFY
      Banks
      Finance
    • Chief Risk Officer Owes Keith bought $9,660 worth of shares (1,000 units at $9.66), increasing direct ownership by 7% to 15,500 units (SEC Form 4)

      4 - Blue Foundry Bancorp (0001846017) (Issuer)

      6/5/25 11:32:57 AM ET
      $BLFY
      Banks
      Finance
    • EVP and Chief Legal Officer Beidner Elyse D. covered exercise/tax liability with 1,195 shares, decreasing direct ownership by 5% to 24,671 units (SEC Form 4)

      4 - Blue Foundry Bancorp (0001846017) (Issuer)

      3/10/25 4:17:27 PM ET
      $BLFY
      Banks
      Finance